Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA LLC, 19325 [2023-06698]
Download as PDF
<![CDATA[
19325
Federal Register / Vol. 88, No. 62 / Friday, March 31, 2023 / Notices
suspension agreements took effect on
March 17, 2023. The antidumping duty
suspension agreement is based upon an
agreement between Commerce and
producers/exporters which account for
substantially all imports of white grape
juice concentrate from Argentina, in
which each signatory producer/exporter
has agreed to revise its prices to
eliminate completely the injurious
effects of exports of WGJC to the United
States. The countervailing duty
suspension agreement is based upon an
agreement between Commerce and the
Government of Argentina (‘‘GOA’’),
wherein the GOA has agreed not to
provide any new or additional export or
import substitution subsidies on the
subject merchandise and has agreed to
restrict the volume of direct or indirect
exports to the United States of WGJC
from all Argentine producers/exporters
in order to eliminate completely the
injurious effects of exports of this
merchandise to the United States.
Accordingly, the U.S. International
Trade Commission gives notice of the
suspension of its antidumping and
countervailing duty investigations
involving imports of WGJC from
Argentina, provided for in subheading
2009.69.00 of the Harmonized Tariff
Schedule of the United States.
DATES:
March 24, 2023.
ddrumheller on DSK120RN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Ahdia Bavari (202–205–3191), Office of
Investigations, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436. Hearingimpaired individuals are advised that
information on this matter can be
obtained by contacting the
Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these investigations may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
Authority: These investigations are
being suspended under authority of title
VII of the Tariff Act of 1930 and
pursuant to section 207.40(b) of the
Commission’s Rules of Practice and
Procedure (19 CFR 207.40(b)). This
notice is published pursuant to section
201.10 of the Commission’s rules (19
CFR 201.10).
By order of the Commission.
VerDate Sep<11>2014
17:54 Mar 30, 2023
Jkt 259001
Issued: March 27, 2023.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2023–06669 Filed 3–30–23; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–23–018]
Sunshine Act Meetings
United
States International Trade Commission.
TIME AND DATE: April 7, 2023 at 11:00
a.m.
PLACE: Room 101, 500 E Street SW,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: none.
2. Minutes.
3. Ratification List.
4. Commission vote on Inv. Nos. 701–
TA–552 and 731–TA–1308 (Review)
(Pneumatic Off-the-Road (OTR) Tires
from India). The Commission currently
is scheduled to complete and file its
determinations and views of the
Commission on April 27, 2023.
5. Outstanding action jackets: none.
CONTACT PERSON FOR MORE INFORMATION:
Sharon Bellamy, Acting Supervisory
Hearings and Information Officer, 202–
205–2000.
The Commission is holding the
meeting under the Government in the
Sunshine Act, 5 U.S.C. 552(b). In
accordance with Commission policy,
subject matter listed above, not disposed
of at the scheduled meeting, may be
carried over to the agenda of the
following meeting.
AGENCY HOLDING THE MEETING:
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 30, 2023. Such persons
may also file a written request for a
hearing on the application on or before
May 30, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on March 3, 2023, Sterling
Pharma USA LLC., 1001 Sheldon Drive,
Suite 101, Cary, North Carolina 27513–
2078, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Controlled substance
Dimethyltryptamine .......
By order of the Commission.
Issued: March 29, 2023.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2023–06864 Filed 3–29–23; 4:15 pm]
BILLING CODE 7020–02–P
Drug
code
7435
Schedule
I
The company plans to manufacture
the above-listed controlled substance(s)
to support clinical trials. No other
activities for this drug code is
authorized for this registration.
Matthew Strait,
Deputy Assistant Administrator.
DEPARTMENT OF JUSTICE
[FR Doc. 2023–06698 Filed 3–30–23; 8:45 am]
Drug Enforcement Administration
BILLING CODE P
[Docket No. DEA–1174]
Bulk Manufacturer of Controlled
Substances Application: Sterling
Pharma USA LLC
Bulk Manufacturer of Controlled
Substances Application: Purisys, LLC
Sterling Pharma USA LLC.
has applied to be registered as a bulk
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
[Docket No. DEA–1172]
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
SUMMARY:
DEPARTMENT OF JUSTICE
Drug Enforcement
Administration, Justice.
AGENCY:
E:\FR\FM\31MRN1.SGM
31MRN1
]]>Agencies
[Federal Register Volume 88, Number 62 (Friday, March 31, 2023)]
[Notices]
[Page 19325]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-06698]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1174]
Bulk Manufacturer of Controlled Substances Application: Sterling
Pharma USA LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Sterling Pharma USA LLC. has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
May 30, 2023. Such persons may also file a written request for a
hearing on the application on or before May 30, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on March 3, 2023, Sterling Pharma USA LLC., 1001 Sheldon
Drive, Suite 101, Cary, North Carolina 27513-2078, applied to be
registered as a bulk manufacturer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Dimethyltryptamine..................... 7435 I
------------------------------------------------------------------------
The company plans to manufacture the above-listed controlled
substance(s) to support clinical trials. No other activities for this
drug code is authorized for this registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023-06698 Filed 3-30-23; 8:45 am]
BILLING CODE P
